Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Tuberous Sclerosis Complex
Interventions
DRUG

RAD001

"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."

DRUG

Placebo

"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."

Trial Locations (2)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

02115

Boston Children's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tuberous Sclerosis Alliance

OTHER

collaborator

Autism Speaks

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Seizure Tracker LLC

UNKNOWN

lead

Mustafa Sahin

OTHER